DOCSLIB.ORG

Today's Research Tomorrow's Cure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Today's Research Tomorrow's Cure 2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease. deposits. • To develop new ways to detect symptoms of cardiovascular disease This is being achieved via scientific and before it leads to clinical problems. clinical research work conducted by the • To develop new treatments that can scientific groups that make up the HRI, reverse the development of heart from basic biomedical discovery work, disease. drug discovery and development, and • To prevent individuals developing devices and device improvement, to cardiovascular disease in the future. clinical trials and clinical initiatives. HRI in 2018 Locations 60+ COLLABORATIONS ACROSS 25 COUNTRIES • 7 Eliza Street, Newtown • Charles Perkins Centre, The University of Sydney Chairman Professor Len Kritharides Director of Cardiovascular Research Professor Shaun Jackson Chief Executive Officer Dr Stephen Hollings Deputy Director Research Strategy Professor Ben Freedman Acting Scientific Director Emeritus Professor Carolyn Geczy Clinical Director Professor David Celermajer 2018 GRANT INCOME 2018 CITATIONS BY FUNDING BODY Associate Directors of Research Management and Education Dr Mary Kavurma (Eliza St) 172 Assoc Professor Simone Schoenwaelder (Charles Perkins Centre) 13 Scientific Groups $1,361,973 $25,488 • Applied Materials (5.35%) (0.10%) 2018 PERSONNEL • Atherosclerosis and Vascular National Health Australian Remodelling and Medical Research • Cardiac Imaging Research Council Council (ARC) 250+ • Cardiometabolic Disease (NHMRC) • Cardiovascular Medical Devices • Cell Therapeutics • Clinical Research • Haematology Research • Heart Rhythm and Stroke Prevention 2018 HRI INCOME • High Blood Pressure • Thrombosis $75,000 $1,024,443 • Vascular Complications (0.29%) (4.03%) • Vascular Immunology National Heart NSW Government Foundation (NHF) (MRSP) Our Partnerships • Charles Perkins Centre, The University of Sydney • Sydney Local Health District and Sydney Health Partners - Royal Prince Alfred Hospital - Sydney Research $2,083,654 $15,000 $20,854,773 Australian Business Number (8.19%) (0.06%) 41 003 209 952 Other Commercial (81.98%) funding TOTAL: $25,440,331 Donations 8 2018 Heart Research Institute Annual Review Chairman’s Report 2018 PROFESSOR LEN KRITHARIDES CROSSING DIVIDES AND prevention, the better application of Clinical research provides relevance, BUILDING BRIDGES established therapies and the identification defining clinical problems and establishing Heart attacks and strokes remain the of new treatments. Community awareness the efficacy and impact of treatments. The commonest cause of mortality and of cardiovascular disease as a contemporary combination of the two, moving from bench morbidity in the Australian population, and cause of premature death and disability to bedside and from bedside to bench, is very in developing countries they are increasing is remarkably low – making our ability to powerful. It is for this reason that since its at an alarming rate. The incidence is deliver optimal prevention and treatment inception, the HRI has always crossed the fuelled by our ageing population and the to the community challenging. divide between basic science and clinical increasing prevalence of diabetes and research, closely linked at its foundation obesity. Combating heart disease and stroke Laboratory science provides mechanistic with the Department of Cardiology at – commonly referred to as cardiovascular understanding – how and why things happen RPAH. Current clinician scientists at the disease – requires increased efforts in – in the great engine room of discovery. HRI include cardiologists (Professors Chairman’s Report 2018 David Celermajer and Ben Freedman, and New Zealand, industry, and NSW Dr Lining (Arnold) Ju an ATVB Career Associate Professor Sanjay Patel and Health. The diversity of external funding Development Award, Dr Steve Wise was Dr John O’Sullivan), renal and obstetric sources reflects the diverse portfolio of awarded the Marshall and Warren Award physician Professor Annemarie Hennessy, research undertaken by HRI scientists – for Most Innovative Project Grant by the haematologist Dr Freda Passam, radiologist from bench to bedside. The contribution NHMRC, and Professor Shaun Jackson Professor Stuart Grieve, and our Director of NSW Health in directly supporting received the CVRN 2018 Ministerial Award of Cardiovascular Research Professor cardiovascular research is especially for Cardiovascular Research Excellence, Shaun Jackson. The ability to cross-appoint notable. It reflects a major change in the presented by The Honourable Brad Hazzard clinicians to RPAH and to the HRI is critical research landscape in NSW, providing MP, NSW Minister for Health and Minister to the ongoing success of the HRI, and career and project support for aspiring for Medical Research. has been strongly supported by the Chief scientists and clinician-scientists, and is The ability of our scientists to undertake Executive of the Sydney Local Health proving critical for the sustainability of such excellent work requires outstanding District, Dr Teresa Anderson. cardiovascular research in NSW. infrastructure and administrative support. The HRI crosses another divide – the divide The partnership with the NSW Government The scientific leadership of the HRI, led by between biological science and chemical was most emphatically demonstrated with Professors Shaun Jackson, Carolyn Geczy discovery. NHMRC-funded collaborative the announcement in 2018 of the NSW and Ben Freedman, the management team research between Professor Shaun Cardiovascular Research Capacity Building of the HRI led by our CEO Dr Stephen Jackson and Professor Richard Payne Grants Program worth $150 million over Hollings, our fundraising team led by from the Department of Chemistry at The 10 years. This major commitment by the Richard Wylie, our human resources lead University of Sydney is discovering new Berejiklian Government, a first for Australia, Elissa Dwyer, and our committed Board chemicals to inhibit the formation of blood represented the culmination of another of Governors and International Trustees/ clots, which may have implications for the collaboration – between the HRI, the Victor Directors deserve our enduring gratitude treatment of critical events such as stroke. Chang Cardiac Research Institute and the and sincere thanks. Such research requires internationally NSW Cardiovascular Research Network This report began by referring to crossing competitive expertise on both fronts – (CVRN) of the Heart Foundation. This peer- divides and building bridges, and I hope biology and chemistry – and an environment reviewed funding pool will be open to all I have given an indication of the importance that encourages collaboration. cardiovascular researchers in NSW, and of partnerships in achieving great science. represents a major increase in the total I would like to finish by acknowledging what is for the HRI its most enduring “ Our scientific achievements are fundamentally partnership – the partnership with you, its members and donors. Our scientific also the achievements of our supporters, and it is achievements are fundamentally also important that we can share the achievements of the achievements of our supporters, and it is important that we can share the our scientists with you.” achievements of our scientists with you. The HRI has always been strongly supported by the enormous goodwill of Other leading scientists at the HRI whose pool of funds available for urgently needed the general community, and that support work straddles biology and bioengineering, cardiovascular research in NSW. The
Load more

Recommended publications
  • 2007 Annual Report Annual Institute Eye Lions Review Molecular
    Lions Eye Institute ABN 48 106 521 439 2 Verdun Street, Nedlands WA 6009 General Administration & Research Enquiries 9381 0777 Administration & Research Facsimile 9381 0700 07 International +61 8 9381 0777 Clinical Facilities Elsie Gadd Eye Clinic Appointments 9381 0888 Day Surgery Facility 9381 0880 Laser Vision Centre 9381 0758 Clinical Facilities Facsimile 9382 1171 Annual REPORT 20 WWW.LEI.ORG.AU RAZOREYE LEI5693 02/08 Lions Eye Institute 2007 Annual Report Annual Report 2007 Corporate Directory Mission Lions Eye Institute Prof. Ian Constable AO Assoc. Prof. Geoffrey Crawford Administration & Finance Our mission is to achieve excellence Managing Director Director of Surgical Services [email protected] [email protected] Chee-Peng Yao in scientific research and clinical practice 9381 0871 Chief Financial Officer Esther McCloskey [email protected] to prevent blindness. Executive Assistant to Prof. Constable Assoc. Prof. Graham Barrett 9381 0703 [email protected] [email protected] 9381 0882 9381 0872 David Eiszele Dr Jean-Louis deSousa Information Technology Chairman [email protected] & Communications 9381 0777 9381 0747 Yaasin Lutta Dr Adam Gajdatsy Head of Information Technology [email protected] & Communications Research 9381 0763 [email protected] 9381 0786 Prof. P. Elizabeth Rakoczy Dr Antonio Giubilato Director of Research; [email protected] Director, Molecular Ophthalmology 9381 0819 [email protected] Lions Eye Bank 9381 0726 Dr Tim Isaacs [email protected] Stephanie Durham Coordinator Assoc. Prof. Mariapia Degli-Esposti 9381 0862 Co-Director, Centre for Experimental [email protected] Immunology; Assoc.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Finding Cures for Cardiovascular Disease Through World-Class Medical Research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03
    IMPACT REPORT 2019 Finding cures for cardiovascular disease through world-class medical research 02 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 03 For years the Victor Chang Cardiac Research Institute has Contents been Australia’s home of heart research. Since , the Institute has made an unshakeable contribution to the fight against About Us 4 Heart Disease Statistics 6 cardiovascular disease, and that PATIENT STORY SCAD Survivor 8 makes us overwhelmingly proud. Chairman’s Report 10 Executive Director’s Report 14 In ­­ we farewell our PATIENT STORY Cardiac Arrest Survivor 16 Organisational Structure 17 pioneering Executive Director, Board of Directors 18 Professor Bob Graham. 25 years of discovery 20 PROFILE Professor Bob Graham 24 Nevertheless, we are confident PROFILE Professor Diane Fatkin 34 that in Professor Jason Kovacic PROFILE Professor Livia Hool 38 Research Divisions Overview 42 we have a champion who will not Victor Chang Cardiac Research Institute Innovation Centre 44 only continue this legacy but take Sohn Hearts & Minds the Institute to the next level, as Investment Leaders Conference 46 Heart Health Checks 48 the new leader of the organisation. Statement of Income and Expenditure 49 Achievements and Awards 50 Fundraising Events 52 Supporters and Acknowledgments 54 This special 25th Anniversary edition is dedicated Support Life-Saving Heart Research 57 to you, our loyal supporters. After a quarter of a century, thanks to you, we’re only just getting started. Here’s to another 25 illustrious years! 04 VICTOR CHANG CARDIAC RESEARCH INSTITUTE IMPACT REPORT 2019 05 About Us Our Mission Our Statistics Australia’s home The relief of pain and suffering and the promotion of wellbeing, of heart research through an understanding of the fundamental The Victor Chang Cardiac Research mechanisms of researchers and staff cardiovascular biology in Institute is dedicated to finding cures health and disease.
    [Show full text]
  • Building Innovation, Performance and Trust
    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
    [Show full text]
  • Annual Report 2005, Baker Heart Research Institute
    Baker Heart Research Institute | Annual Report 2005 Annual Report 2005 Contents 2 The Baker story 4 Organisational Structure 6 Director’s Report 8 President’s Report 9 A word from our patron 10 The Board 12 Baker History 14 Summary of Baker relationships 15 Research & Divisions 16 Baker Clinical 17 ABMU 18 Experimental Cardiology and Heart Failure 19 Wynn Department of Cardiology 20 Cellular Biochemistry 21 Experimental Cardiology 22 Cardiac Hypertrophy 23 Cardiac Surgery 24 Applied Cardiovascular Research 25 Molecular Endocrinology 26 Molecular Pharmacology 27 Atherothrombosis and Vascular 28 Thrombosis & Myocardial Infarction 29 Cell Biology 30 Clinical Physiology 31 Vascular Pharmacology 32 Cell Biology & Diabetes 33 Lipoproteins & Atherosclerosis 34 Human & Vascular Biology 35 JDRF Diabetes and Metabolism 36 Oxidative Stress 37 Human Epigenetics 38 Biochemistry of Diabetic Complications 39 Kidney Disease in Diabetic Complications 40 Advanced Glycation in Diabetic Complications 41 Genomics of Diabetic Complications 42 Proliferation & Fibrosis in Diabetic Complications 43 Atherosclerosis in Diabetic Complications 44 Cardiovascular Neuroscience 45 Neuropharmacology 46 Translational Proteomics Ramaciotti Centre 47 Human Neurotransmitters 48 Commercialisation 60 Core Facilities 62 Staff & Students 66 Monthly Baker Science Awards 68 Development 67 Donors 70 Financial Report 73 Publications 76 Location & Contact details now in its 80th year, the Baker A comprehensive research Heart Research Institute is program with a strategic focus: The Baker story… Australia’s most distinguished Research at the Baker is broadly cardiovascular research centre divided into four divisions: and one of the world’s leading Experimental Cardiology and Heart organisations investigating Failure; Atherothrombosis and the causes and complications, Vascular; Diabetes and Metabolism treatment and prevention of heart, and Cardiovascular Neuroscience.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]
  • Snow Fellowship 2021 Application Round - Eligible Host Organisations
    Snow Fellowship 2021 Application Round - Eligible Host Organisations Entity name Asbestos Diseases Research Institute Australian Catholic University Limited Australian Centre for Heart Health Australian Institute of Aboriginal and Torres Strait Islander Studies Australian National University Baker Heart and Diabetes Institute Bionics Institute Black Dog Institute Bond University Limited Brien Holden Vision Institute Burnet Institute Centenary Institute of Cancer Medicine and Cell Biology Central Australian Aboriginal Congress Aboriginal Corporation Central Queensland University Centre for Eye Research Australia Limited Charles Darwin University Charles Sturt University Children's Cancer Institute Children's Medical Research Institute Chris O'Brien Lighthouse Curtin University Deakin University Doherty Institute Ear Science Institute Australia Incorporated Edith Cowan University Federation University Australia Flinders University Florey Institute of Neuroscience and Mental Health Garvan Institute of Medical Research George Institute for Global Health Griffith University Hanson Institute Harry Perkins Institute of Medical Research Heart Research Institute Hudson Institute of Medical Research Hunter Medical Research Institute Ingham Institute Institute for Breathing and Sleep James Cook University Kolling Institute of Medical Research La Trobe University Lions Eye Institute Macquarie University Snow Fellowship 2021 Application Round - Eligible Host Organisations Mater Research Limited Melanoma Institute Australia Menzies School of Health
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • Snow Fellowships 2020 Application Round - Eligible Host Organisations
    Snow Fellowships 2020 Application Round - Eligible Host Organisations Entity name Asbestos Diseases Research Institute Australian Catholic University Limited Australian Centre for Heart Health Australian Institute of Aboriginal and Torres Strait Islander Studies Australian National University Baker Heart and Diabetes Institute Bionics Institute Black Dog Institute Bond University Limited Brien Holden Vision Institute Burnet Institute Centenary Institute of Cancer Medicine and Cell Biology Central Australian Aboriginal Congress Aboriginal Corporation Central Queensland University Centre for Eye Research Australia Limited Charles Darwin University Charles Sturt University Children's Cancer Institute Children's Medical Research Institute Chris O'Brien Lighthouse Curtin University Deakin University Doherty Institute Ear Science Institute Australia Incorporated Edith Cowan University Federation University Australia Flinders University Florey Institute of Neuroscience and Mental Health Garvan Institute of Medical Research George Institute for Global Health Griffith University Hanson Institute Harry Perkins Institute of Medical Research Heart Research Institute Hudson Institute of Medical Research Hunter Medical Research Institute Ingham Institute Institute for Breathing and Sleep James Cook University Kolling Institute of Medical Research La Trobe University Lions Eye Institute Macquarie University Mater Research Limited Melanoma Institute Australia Menzies School of Health Research Monash University Murdoch Children’s Research Institute Murdoch
    [Show full text]
  • Glaxosmithkline, Parent Company of Stiefel, a GSK Company
    Dermatology on Wall Street GlaxoSmithKline, Parent Company of Stiefel, a GSK Company or more than 160 years, Stiefel, a GSK compa- ny, has been committed to dermatology. Following a series of acquisitions in the latter Fpart of the last decade (Connetics Corp. in 2006 and Barrier Therapeutics in 2008), Stiefel itself was acquired by GlaxoSmithKline (GSK) in July 2009. GSK, a global pharmaceutical company, GSK (NYSE: GSK) Founded: 2000 has the third highest revenues of any pharmaceuti- (Merger of Glaxo Wellcome and SmithKline Beecham) cal company globally. The company’s primary therapeutic areas include asthma, anti-virals, anti- Stiefel Founded: 1847, Acquired by GSK in 2009 infectives, cancer, diabetes, mental health, and now dermatology. Its large consumer division mar- Based: London, UK and Research Triangle Park, NC (Stiefel) kets several market-leading products, including the Number of Employees: 96,500+ world’s fastest growing toothpaste brand for the last five years (Sensodyne). On the Web: www.gsk.com Since the acquisition, Stiefel remains focused on www.stiefel.com dermatology, with a portfolio of OTC and prescrip- tions drugs for the treatment in a wide range of Officers: Andrew Witty, Chief Executive Office; Simon Bicknell, dermatologic therapeutic areas, including acne, Senior Vice President, Governance, Ethics and Assurance; John psoriasis, aesthetics, antifungal, anti-itch, and dry Clarke, President, Consumer Healthcare; Deirdre Connelly, skin. President, North American Pharmaceuticals; Simon Dingemans, Stiefel’s development in recent years has Chief Financial Officer; Marc Dunoyer, President, Asia focused on novel foam vehicle formulations, Pacific/Japan; Eddie Gray, President, Pharmaceuticals Europe; including recent additions Sorilux (calcipotriene) Abbas Hussain, President, Emerging Markets and Asia Pacific; and Extina (ketoconazole), and the antibacterial Altabax (retapamulin ointment).
    [Show full text]
  • FAMIS Formulary (Current)
    VIRGINIA PREMIER HEALTH PLAN FAMIS MEDICAID FORMULARY PLEASE NOTE: Check your benefit materials for the specific drugs covered and the copayments for your prescription drug program. For specific questions about your coverage, please call the phone number printed on your ID card. The list may not be all- inclusive. THIS LIST IS SUBJECT TO CHANGE. For the member: Generic medications contain the same active ingredients as their corresponding brand-name medications, although they may look different in color or shape. They have been FDA-approved under strict standards. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you. CURRENT AS OF 10/1/2021 Requirements/Limits AGE = Age limit requirement Custom = Drug has unique restrictions OTC = Over the Counter PA = Prior Authorization required QL = Quantity Level Limit lowercase italics = Generic Formulary SP = Specialty Drug. Preferred Specialty drugs Pharmacy will be listed if applicable UPPERCASE = Brand name Formulary Formulary Status ST = Step Therapy may apply to some or all drugs Formulary = Covered strengths of the drug Drug Name Formulary Status Requirements/Limits 1st relief spray external liquid 4-1 % Formulary OTC 1st tier unifine pentips 29g x 12mm , 31g x 5 mm , 31g x 6 Formulary OTC; QL (200 EA per 30 days) mm , 31g x 8 mm , 32g x 4 mm 1st tier unilet comfortouch Formulary OTC; QL (150 EA per 30 days) 4-N-1 EXTERNAL CREAM 1 % Formulary OTC 50+ adult eye health oral capsule Formulary OTC A & D ZINC OXIDE EXTERNAL
    [Show full text]